The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment

In recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Mengmeng, Xiong, Weiping, Wang, Shiyuan, Li, Yingying, Hou, Chunying, Li, Chunyu, Li, Guohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789882/
https://www.ncbi.nlm.nih.gov/pubmed/35097033
http://dx.doi.org/10.3389/fcvm.2021.821663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789882/
https://www.ncbi.nlm.nih.gov/pubmed/35097033
http://dx.doi.org/10.3389/fcvm.2021.821663

Ejemplares similares